Nektar, Evommune capitalize on positive Phase II readouts in atopic dermatitis: Public Equity Report

A pair of catalyst-driven financings headlined at least five nine-figure deals this week, as companies took advantage of positive clinical readouts or the opportunity to add specialist investors to their shareholder base via PIPE transactions.

Nektar Therapeutics Inc. (NASDAQ:NKTR) raised the largest follow-on of the week in an upsized $400 million deal of common stock and pre-funded warrants. The catalyst-driven financing came about a week after the biotech announced positive Phase II data for its IL-2R modulator rezpegaldesleukin in atopic dermatitis, which drove its shares up 51% on the day it was announced. ...